ORB provides reliable quantitation of up to 60 protein analytes per biofluid sample with custom multiplex protein profiling panels using the Luminex xMAP technology. Click here for information about the Luminex technology. Luminex assays are customizable enabling the measurement of the specific analytes that are relevant to your research. These assays have a dynamic range of 1,000—10,000 fold and sensitivity as low as 0.1pg/mL.
Where analytes cannot be multiplexed ORB provides immunoassay profiling using ELISA kits. Plate-based biochemical and/or enzymatic assays are also available for measurement of enzymes without suitable antibodies or for cases where the activity is more important then the mass present.
ORB’s competitively priced service examines a wide variety of biofluids. Pilot studies are available to determine the optimal dilution range for each sample type. Protein profiling studies can be performed under good laboratory practice (GLP) certification upon request. Please see the multiplex protein profiling page for additional details about ORB's Luminex-based immunoassay services, and the quality assurance page for additional information about GLP. The biomarker discovery page provides a broad overview of ORB's capability to assist clients with marker discovery and development.
Biofluid Sample Types for Immunoassay Services
- Cerebrospinal Fluid
- Bronchial lavage
- Contact us about other biofluid sample types.
ORB is a Biosafety Level 2 (BSL-2) laboratory, equipped with trained scientists to handle biofluid samples containing infectious agents such as human immuno deficiency I or hepatitis C viruses.
Biofluid-based Biomarkers Available for Multiplex Protein Profiling
- Oncology: circulating tumors, angiogenesis, metastasis
- Cardiovascular disease biomarkers
- Immunology: cytokines/chemokines
- Intracellular pathways: cell signaling, cell metabolism
- Endocrinology: gut hormones, adipokines, muscle and bone biomarkers
- Neuroscience: neurodegenerative disease, neurological disorders, neuropeptides/ neurohormone signaling
- Kidney toxicity, liver and vascular injury
Utlilize ORB's custom panel selection tool on the protein profiling page to efficiently peruse hundreds of species specific analytes for many diseases.
Biofluid volumes are assay dependent; however, most assays require a minimum submission of 125 ul per sample. Citrate or EDTA tubes are recommended for collection of plasma, and a serum separator tube is recommended to obtain the best results with serum collection procedures.
|Sample Type||Sample Preparation Protocol||Sample Submission Checklist|
|Biofluids||See sample submission checklist||Protein Analysis - Biofluids|
Please review our suggestions prior to sample preparation and shipping to ensure maximum protection of your samples. Please call 754-600-5128 or contact us through the Contact Form in order to discuss projects with unique requirements or to obtain customized instructions for sample preparation and shipping that are adapted to your unique situation.
Demonstration of biofluid profiling with ORB’s immunoassay service
Pediatric Inflammatory Bowel Disease
Protein immunoaffinity-based assays, e.g. multiplex assays, provide a highly-sensitive, reliable, and efficient approach to identifying biomarkers within biofluid samples collected via minimally invasive strategies. Although biomarkers are most commonly associated with oncology, significant literature exists in many disease areas demonstrating the detection of biological markers relevant to understand pathological mechanisms or treatment effects. Researchers at the Medical College of Wisconsin and the Mayo Clinic utilized ORB’s multiplex protein profiling service to examine potential immunoregulatory signatures associated with inflammatory bowel disease (IBD) in newly diagnosed pediatric patients. In this study ORB analyzed cytokine levels within plasma samples from patients having Crohn’s disease and ulcerative colitis using a multiplex assay1.
Neuroblastomas comprise approximately 15% of childhood cancer deaths and present a surprising diversity of clinical outcomes2. For example, while complete regression with minimal treatment is experienced by most infants, even with once metastasis ensues, older patients often experience an unrelenting progression of the disease, despite multi-modality therapies. As a result, age at diagnosis is utilized, in part, to stratify neuroblastoma patients into a low, intermediate, or high risk categories3. This age dependent response to neuroblastoma appears to be related to a reliance on the innate immune system in infancy, opposed to a more prominent adaptive immune in older patients. Researchers from the Children's Hospital of Richmond and the Virginia Commonwealth University investigated the innate and adaptive immune responses of patients with high and low risk neuroblastoma4. ORB's immunoassay services were utilized in this study to quantitate 12 analytes from human serum samples using a BioRad Bio-Plex cytokine assay. Findings from this work showed that LR patients have higher levels of cytokines involved in the innate immune system as well as reduced T cell responses.
- Gurram, B., Salzman, N. H., Kaldunski, M. L., Jia, S., Li, B. U. K., Stephens, M., & Hessner, M. J. (2016). Plasma‐induced signatures reveal an extracellular milieu possessing an immunoregulatory bias in treatment‐naive paediatric inflammatory bowel disease. Clinical & Experimental Immunology, 184(1), 36-49.
- Maris, J. M., & Matthay, K. K. (1999). Molecular biology of neuroblastoma. Journal of clinical oncology, 17(7), 2264-2264.
- London, W. B., Castleberry, R. P., Matthay, K. K., Look, A. T., Seeger, R. C., Shimada, H., & Cohn, S. L. (2005). Evidence for an age cutoff greater than 365 days for neuroblastoma risk group stratification in the Children's Oncology Group. Journal of Clinical Oncology, 23(27), 6459-6465.
- Gowda, M., Godder, K., Kmieciak, M., Worschech, A., Ascierto, M. L., Wang, E., ... & Manjili, M. H. (2011). Distinct signatures of the immune responses in low risk versus high risk neuroblastoma. Journal of translational medicine, 9(1), 170.